Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel and CPT-11 in Second Line Gastric Cancer
NCT00209612Phase 2Withdrawn
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
- Start
- Apr 2004
- Primary completion
- Nov 2008
- Modality
- Small Molecules, Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in gastric cancer (GC), sponsored by Hokkaido Gastrointestinal Cancer Study Group. Primary endpoints: Dose Limiting Toxicity at 1 year, Maximum Tolerated Dose at 1 year and 1 more. Planned start Apr 2004; status: withdrawn.
02
Drugs
Paclitaxel Micelles for Injectionirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00209612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00209612.